Form Type: 4

SEC EDGAR Link
Accession Number:0001144204-15-012346
Date:2015-02-24
Issuer: SEATTLE GENETICS INC /WA (SGEN)
Original Submission Date:

Reporting Person:

BAKER FELIX
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065

Reporting Person:

BAKER JULIAN
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065

Reporting Person:

BAKER BROS. ADVISORS (GP) LLC
667 MADISION AVENUE 21ST FLOOR
NEW YORK, NY US 10065

Reporting Person:

BAKER BROS. ADVISORS LP
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065

Reporting Person:

667, L.P.
667 MADISON AVENUE 21ST FLOOR
NEW YORK, NY US 10065

Reporting Person:

BAKER BROTHERS LIFE SCIENCES LP
667 MADISON AVENUE, 21ST FLOOR
NEW YORK, NY US 10065

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
COMMON STOCK 2015-02-24 P 49,416 a $33.65 24,042,560 indirect f5,f9
COMMON STOCK 2015-02-24 P 4,995 a $33.60 24,047,555 indirect f5,f9
COMMON STOCK 2015-02-24 P 163,054 a $33.80 24,210,609 indirect f5,f9
COMMON STOCK 2015-02-25 P 62,650 a $34.46 24,273,259 indirect f5,f9
COMMON STOCK 2015-02-25 P 1,000 a $35.60 24,274,259 indirect f5,f9
COMMON STOCK 2015-02-24 0 $0.00 107,511 direct
COMMON STOCK 2015-02-24 0 $0.00 107,504 direct
COMMON STOCK 2015-02-24 0 $0.00 3,885,576 indirect f9
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
Footnotes
IDfootnote
f1 reflects shares of common stock of the issuer held directly by felix j. baker.
f2 reflects shares of common stock of the issuer held directly by julian c. baker.
f3 as a result of their ownership interest in baker biotech capital (gp), llc, felix j. baker and julian c. baker may be deemed to have an indirect pecuniary interest in 3,885,576 shares of common stock of the issuer beneficially owned by 667, l.p. ("667"), a limited partnership of which the sole general partner is baker biotech capital, l.p., a limited partnership of which the sole general partner is baker biotech capital (gp), llc, due to baker biotech capital, l.p.'s right to receive an allocation of a portion of the profits from 667.
f4 the price reported in column 4 is a weighted average price. these shares were purchased by baker brothers life sciences, l.p. ("life sciences") in multiple transactions at prices ranging from $33.47 to $33.75, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
f5 after giving effect to the transactions reported herein and as a result of their ownership interest in baker brothers life sciences capital (gp), llc, julian c. baker and felix j. baker each may be deemed to have an indirect pecuniary interest in the issuer's shares of common stock reported in column 5 of table i directly held by life sciences, a limited partnership of which the sole general partner is baker brothers life sciences capital, l.p., a limited partnership of which the sole general partner is baker brothers life sciences capital (gp), llc, due to baker brothers life sciences capital, l.p.'s right to receive an allocation of a portion of the profits from life sciences.
f6 the price reported in column 4 is a weighted average price. these shares were purchased by life sciences in multiple transactions at prices ranging from $33.50 to $33.70, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
f7 the price reported in column 4 is a weighted average price. these shares were purchased by life sciences in multiple transactions at prices ranging from $33.41 to $34.09, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
f8 the price reported in column 4 is a weighted average price. these shares were purchased by life sciences in multiple transactions at prices ranging from $34.20 to $34.68, inclusive. the reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.
f9 baker bros. advisors lp (the "adviser") serves as the investment adviser to life sciences and 667, (collectively the "funds"). in connection with the services provided by the adviser, the adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the funds. baker bros. advisors (gp) llc (the "adviser gp") is the adviser's sole general partner. julian c. baker and felix j. baker are principals of the adviser gp. the adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the funds. the general partners of the funds relinquished to the adviser all discretion and authority with respect to the investment and voting power of the securities held by the funds. julian c. baker, felix j. baker, the adviser gp and the adviser disclaim beneficial ownership of the securities held directly by the funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of julian c. baker, felix j. baker, the adviser gp or the adviser is a beneficial owner of such securities for purposes of section 16 or any other purpose.
WhaleWisdom Logo

Elevate your investments